189 related articles for article (PubMed ID: 15603184)
1. Lessons from preventive infectious disease vaccines.
Chandler DK; Midthun K; Goldenthal KL
Dev Biol (Basel); 2004; 116():61-6; discussion 69-76. PubMed ID: 15603184
[TBL] [Abstract][Full Text] [Related]
2. Review of current preclinical testing strategies for bacterial vaccines.
Falk LA; Chandler DK; Richman P
Dev Biol Stand; 1998; 95():25-9. PubMed ID: 9855411
[TBL] [Abstract][Full Text] [Related]
3. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
4. Lessons learned from a review of the development of selected vaccines. National Vaccine Advisory Committee.
Peter G; des Vignes-Kendrick M; Eickhoff TC; Fine A; Galvin V; Levine MM; Maldonado YA; Marcuse EK; Monath TP; Osborn JE; Plotkin S; Poland GA; Quinlisk MP; Smith DR; Sokol M; Soland DB; Whitley-Williams PN; Williamson DE; Breiman RF
Pediatrics; 1999 Oct; 104(4 Pt 1):942-50. PubMed ID: 10506239
[TBL] [Abstract][Full Text] [Related]
5. Development and approval of vaccines in the United States.
Botstein P
Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
[TBL] [Abstract][Full Text] [Related]
6. Regulation and review of DNA vaccine products.
Smith HA
Dev Biol (Basel); 2000; 104():57-62. PubMed ID: 11713825
[TBL] [Abstract][Full Text] [Related]
7. Regulation of vaccines: strengthening the science base.
Milstien JB
J Public Health Policy; 2004; 25(2):173-89; discussion 190-6. PubMed ID: 15255384
[TBL] [Abstract][Full Text] [Related]
8. Regulatory issues relating to the use of recombinant vectors in production of human vaccines.
Marcus-Sekura CJ
Dev Biol Stand; 1994; 82():107-12. PubMed ID: 7958464
[TBL] [Abstract][Full Text] [Related]
9. Potency assays for therapeutic live whole cell cancer vaccines.
Petricciani J; Egan W; Vicari G; Furesz J; Schild G
Biologicals; 2007 Apr; 35(2):107-13. PubMed ID: 16882459
[TBL] [Abstract][Full Text] [Related]
10. New challenges in assuring vaccine quality.
Dellepiane N; Griffiths E; Milstien JB
Bull World Health Organ; 2000; 78(2):155-62. PubMed ID: 10743279
[TBL] [Abstract][Full Text] [Related]
11. Assuring the quality, safety, and efficacy of DNA vaccines.
Robertson JS; Griffiths E
Methods Mol Med; 2006; 127():363-74. PubMed ID: 16988466
[TBL] [Abstract][Full Text] [Related]
12. Assuring the quality, safety, and efficacy of DNA vaccines.
Robertson JS; Griffiths E
Mol Biotechnol; 2001 Feb; 17(2):143-9. PubMed ID: 11395863
[TBL] [Abstract][Full Text] [Related]
13. Extraneous agents testing for substrates of avian origin and viral vaccines for poultry: current provisions and proposals for future approaches.
Jungbäck C; Motitschke A
Biologicals; 2010 May; 38(3):362-5. PubMed ID: 20335053
[TBL] [Abstract][Full Text] [Related]
14. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
15. Moving new vaccines for tuberculosis through the regulatory process.
Brennan MJ
Clin Infect Dis; 2000 Jun; 30 Suppl 3():S247-9. PubMed ID: 10875792
[TBL] [Abstract][Full Text] [Related]
16. Vaccines for otitis media: proposals for overcoming obstacles to progress.
Murphy TF; Bakaletz LO; Kyd JM; Watson B; Klein DL
Vaccine; 2005 Apr; 23(21):2696-702. PubMed ID: 15780715
[TBL] [Abstract][Full Text] [Related]
17. US FDA review and regulation of preventive vaccines for infectious disease indications: impact of the FDA Amendments Act 2007.
Gruber MF
Expert Rev Vaccines; 2011 Jul; 10(7):1011-9. PubMed ID: 21806396
[TBL] [Abstract][Full Text] [Related]
18. Current regulatory issues in cell and tissue therapy.
Burger SR
Cytotherapy; 2003; 5(4):289-98. PubMed ID: 12944234
[TBL] [Abstract][Full Text] [Related]
19. Consistency testing of diphtheria and tetanus to replace potency testing for lot release.
Kreeftenberg JG
Dev Biol (Basel); 2002; 111():291-8. PubMed ID: 12678252
[TBL] [Abstract][Full Text] [Related]
20. Developing an approach to evaluate the use of neoplastic cells as vaccine substrates.
Lewis AM
Dev Biol (Basel); 2001; 106():37-42; discussion 42-3. PubMed ID: 11761251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
